bion-1301
mAbexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Nov 15, 2017 (NCT03340883)
Timeline
Indications
Mechanism of action
TNFSF13 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095316 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07146906 | Phase 2 | Nov 18, 2025 | Novartis |
| NCT06858319 | Phase 3 | Jul 28, 2025 | Novartis |
| NCT05852938 | Phase 3 | Jun 27, 2023 | Chinook Therapeutics |
| NCT05508204 | Phase 1 | Jul 19, 2022 | Chinook Therapeutics |
| NCT04684745 | Phase 2 | Sep 10, 2020 | Chinook Therapeutics |
| NCT03945318 | Phase 1 | Apr 8, 2019 | Aduro BioTech |
| NCT03340883 | Phase 1/Phase 2 (Phase 2) | Nov 15, 2017 | Aduro BioTech |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinook Therapeutics | For profit | 3 | 3 | 3 | 2020 |
| Aduro BioTech | For profit | 2 | 2 | 2 | 2017 |
| Novartis | For profit | 2 | 2 | 2 | 2025 |
3 organizations
Page 1 / 1